Article

Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication.

State Key Laboratory of Elemento-Organic Chemistry, National Pesticide Engineering Research Center (Tianjin), Nankai University, Tianjin 300071, China.
European journal of medicinal chemistry (impact factor: 3.27). 01/2010; 45(5):1919-26. DOI:10.1016/j.ejmech.2010.01.032 pp.1919-26
Source: PubMed

ABSTRACT A series of new acrylamide derivatives containing 1,2,3-thiadiazole were synthesized, characterized, and evaluated for their anti-hepatitis B virus (HBV) activities in vitro. The IC50 of compounds 9b (10.4 microg/mL), 9c (3.59 microg/mL) and 17a (9.00 microg/mL) of the inhibition on the replication of HBV DNA were higher than that of the positive control lamivudine (14.8 microg/mL). Compound 9d exhibited significant activity against secretion of HBeAg (IC50=12.26 microg/mL).

0 0
 · 
0 Bookmarks
 · 
25 Views
  • Source
    Article: Discovery and development of anti-HBV agents and their resistance.
    Kyun-Hwan Kim, Nam Doo Kim, Baik-Lin Seong
    [show abstract] [hide abstract]
    ABSTRACT: Hepatitis B virus (HBV) infection is a prime cause of liver diseases such as hepatitis, cirrhosis and hepatocellular carcinoma. The current drugs clinically available are nucleot(s)ide analogues that inhibit viral reverse transcriptase activity. Most drugs of this class are reported to have viral resistance with breakthrough. Recent advances in methods for in silico virtual screening of chemical libraries, together with a better understanding of the resistance mechanisms of existing drugs have expedited the discovery and development of novel anti-viral drugs. This review summarizes the current status of knowledge about and viral resistance of HBV drugs, approaches for the development of novel drugs as well as new viral and host targets for future drugs.
    Molecules 09/2010; 15(9):5878-908. · 2.39 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

anti-hepatitis B virus
 
Compound 9d exhibited significant activity
 
compounds 9b
 
HBV
 
HBV DNA
 
inhibition
 
new acrylamide derivatives
 

Wei-Li Dong